Characterizing prior nephrectomy patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib versus interferon-alfa

被引：0
|
作者：
Figlin, R. A. [1 ]
Hutson, T. E. [2 ]
Tomczak, P. [3 ]
Michaelson, M. D. [4 ]
Bjarnason, G. A. [5 ]
Lin, X. [6 ]
Lowenthal, S. Pitman [7 ]
Korytowsky, B. [8 ]
Matczak, E. [9 ]
Oudard, S. [10 ]
机构：
[1] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA
[2] Baylor Sammons Canc Ctr Texas Oncol, GU Oncol Program, Dallas, TX USA
[3] Uniwersytet Med, Klin Onkol, Poznan, Poland
[4] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[5] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[6] Pfizer Oncol, Biostat, La Jolla, CA USA
[7] Pfizer Oncol, Asia Pacific Canada Med Oncol, New York, NY USA
[8] Pfizer Global Pharmaceut, Oncol Hlth Econ Outcomes Res, New York, NY USA
[9] Pfizer Oncol, Med Oncol, New York, NY USA
[10] Univ Paris 05, Hop Europeen Georges Pompidou, Paris, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2708
引用
收藏
页码：S644 / S645
页数：2
相关论文
共 50 条
  • [1] Economic evaluations of sunitinib versus interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
    Remak, E.
    Mullins, C. D.
    Akobundu, E.
    Charbonneau, C.
    Woodruff, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON-ALFA (IFN-□) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)
    Szczylik, C.
    Negrier, S.
    Oudard, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I
    Motzer, R. J.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 182 - 182
  • [3] Economic evaluation of sunitinib vs. interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
    Negrier, S.
    Remak, E.
    Brown, R.
    Kim, S. T.
    Charbonneau, C.
    Motzer, R. J.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 303 - 303
  • [4] Final quality of life (QOL) results with geographical analysis for sunitinib versus interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Cella, D.
    Michaelson, M. D.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Charbonneau, C.
    Kim, S. T.
    Li, J. Z.
    Motzer, R. J.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 176 - 176
  • [5] Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results
    Cella, D.
    Michaelson, M. D.
    Cappelleri, J. C.
    Bushmakin, A. G.
    Charbonneau, C.
    Kim, S. T.
    Li, J. Z.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] FINAL QUALITY OF LIFE (QOL) RESULTS WITH GEOGRAPHICAL ANALYSIS FOR SUNITINIB VERSUS INTERFERON-ALFA, AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Cella, D.
    Michaelson, M. D.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Charbonneau, C.
    Kim, S. T.
    Li, J. Z.
    Motzer, R. J.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A283 - A283
  • [7] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Negrier, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 190 - 190
  • [8] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Negrier, S.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors
    Motzer, R. J.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Bukowski, R. M.
    Rixe, O.
    Bjarnason, G. A.
    Kim, S. T.
    Chen, I.
    Michaelson, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Sunitinib plus interferon-alfa in the first-line treatment for metastatic renal cell carcinoma (mRCC): results of a dose-finding study
    Kondagunta, G. V.
    Hudes, G.
    Figlin, R.
    Wilding, G.
    Hariharan, S.
    Kempin, S.
    Fayyad, R.
    Hoosen, S.
    Motzer, R. J.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 305 - 305
12345